Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | SI | P14410 | 3/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612280 | 1.00 | MAPT (0.41) | MAPTHTTHPGDF3CYP1A2 | |
| SCHEMBL21612276 | 1.00 | MAPT (0.41) | MAPTHTTHPGDF3CYP1A2 | |
| SCHEMBL21612277 | 1.00 | MAPT (0.41) | MAPTHTTHPGDF3CYP1A2 | |
| SCHEMBL21614902 | 0.80 | MAPT (0.39) | MAPTHTTHPGDF3CYP1A2 | |
| SCHEMBL23775136 | 0.78 | MAPT (0.36) | MAPTHTTHPGDF3CYP1A2 | |
| SCHEMBL4471849 | 0.76 | ALDH1A1 (0.45) | MAPTHTTHPGDGAAITGB3 | |
| SCHEMBL4471855 | 0.76 | ALDH1A1 (0.45) | MAPTHTTHPGDGAAITGB3 | |
| SCHEMBL21612612 | 0.73 | HTT (0.38) | MAPTHTTHPGDF3CYP1A2 | |
| SCHEMBL21612611 | 0.73 | HTT (0.38) | MAPTHTTHPGDF3CYP1A2 | |
| SCHEMBL6284064 | 0.71 | ALDH1A1 (0.43) | MAPTHTTHPGDGAAITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| WO-2020008317-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, FFAR3, PTGES3 | MAPT 4878/4885HTT 4699/4885HPGD 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.